SEAVUE: a Sea of Change in Biologic Positioning for Crohn’s Disease
Evidence-Based GI: An ACG Publication and Podcast - Een podcast door American College of Gastroenterology - Woensdagen
Bharati Kochar, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd discuss “Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial,” by Sands BE, Irving PM, Hoops T, et al. Lancet [2022;399(10342):2200-2211].
